Vascular Endothelial Growth Factor Inhibitors for Ocular and Selected Indications — CPB 0701 | AETNA Coverage Update

Aetna modified CPB 0701 covering VEGF inhibitors for ocular indications, effective December 20, 2025. Here's what billing teams need to act on now.

Aetna, a CVS Health company, updated Clinical Policy Bulletin 0701, which governs coverage for vascular endothelial growth factor (VEGF) inhibitors used in the eye. This update affects intravitreal injections billed under CPT 67028, HCPCS codes J0177, J0178, J0179, J2777, J2778, J2779, and a full roster of biosimilar Q codes. If your practice treats diabetic macular edema, wet AMD, or retinal vein occlusion, this coverage policy touches every VEGF injection you bill to Aetna commercial plans.

Quick-Reference Table

Aetna VEGF Inhibitor Coverage Criteria and Medical Necessity Requirements 2025

The real issue with CPB 0701 Aetna isn't what's covered—it's the precertification wall you hit if you miss a step. Aetna requires prior authorization for aflibercept (Eylea, Eylea HD), all aflibercept biosimilars (Yesafili/Q5155, Ahzantive/Q5150, Enzeevu/Q5149, Pavblu/Q5147, Opuviz/Q5153), brolucizumab-dbll (Beovu/J0179), faricimab-svoa (Vabysmo/J2777), ranibizumab (Lucentis/J2778), ranibizumab via implant (Susvimo/J2779), and all ranibizumab biosimilars (Cimerli/Q5128, Byooviz/Q5124). Call (866) 752-7021 or fax (888) 267-3277 to precertify. No precert, no reimbursement—it's that simple.

Bevacizumab (Avastin/C9257 or J9035) and its biosimilars are also covered for ocular use, but note the code split: C9257 covers the intraocular 0.25 mg dose, and J9035 covers the 10 mg chemotherapy vial. Using J9035 for an intravitreal compounded dose in an ophthalmology setting is a common source of claim denial. Get that right before December 20, 2025.

Medical necessity for initial approval requires one of the covered indications listed in Section I of the policy. The standard indications for aflibercept and its biosimilars are diabetic macular edema, diabetic retinopathy, macular edema following retinal vein occlusion, neovascular (wet) AMD, and retinopathy of prematurity. Not every agent covers every indication—only Eylea and the biosimilars (Ahzantive, Enzeevu, Opuviz, Pavblu, Yesafili) cover macular edema following retinal vein occlusion and retinopathy of prematurity. Eylea HD does not cover those two.

Continuation of therapy requires documented positive clinical response. That means improvement or maintenance in best corrected visual acuity (BCVA), improvement in visual field, or a reduction in the rate of vision decline. If your notes don't clearly capture one of those outcomes at each visit, your reauthorization request will bounce. Train your clinical staff to document BCVA values at every injection encounter—not just at baseline.

This Aetna VEGF inhibitor coverage policy applies to commercial plans only. Medicare members follow separate criteria. Check the Aetna Medicare Part B step therapy guidelines before assuming this CPB applies to your dual-eligibles.

Aetna VEGF Inhibitor Exclusions and Non-Covered Indications

Aetna calls out two CPT codes as not covered for the indications listed in CPB 0701: CPT 66030 (injection into the anterior chamber of the eye) and CPT 68200 (subconjunctival injection). If you're delivering a VEGF agent by either of those routes, Aetna does not consider it medically necessary under this policy. Billing 67028 for an intravitreal injection and 66030 or 68200 for an anterior chamber or subconjunctival approach are not interchangeable—these are anatomically distinct procedures with distinct coverage status.

For aflibercept agents, any indication not listed in Section I is explicitly considered not medically necessary, experimental, investigational, or unproven. Don't assume coverage because a physician orders it. If the ICD-10 on the claim doesn't map to one of the five covered indications for the specific agent dispensed, you're looking at a denial.

Coverage Indications at a Glance

Aetna VEGF Inhibitor Billing Guidelines and Action Items 2025

CPT, HCPCS, and ICD-10 Codes for VEGF Inhibitors Under CPB 0701

Covered CPT Codes (When Selection Criteria Are Met)

Not Covered CPT Codes for Indications Listed in CPB 0701

Covered HCPCS Codes (When Selection Criteria Are Met)

Key ICD-10-CM Diagnosis Codes

The full ICD-10 list for CPB 0701 contains 1,575 codes. Below are the clinically relevant categories your billing team will use most often for VEGF inhibitor billing. These come directly from the policy data.

For the complete 1,575-code ICD-10 list, see CPB 0701 on PayerPolicy.